Description
Baloxavir Marboxil API is a cap-dependent endonuclease inhibitor that impedes the growth and spread of influenza virus in its finished dose. Baloxavir Marboxil specifically targets and binds to the influenza polymerase acidic (PA) protein, inhibiting its CEN activity. This inhibition of PA endonuclease halts the replication of influenza virus mRNA, resulting in a reduction of viral load. It was approved for medical use both in Japan and in the United States in 2018.